



# Biliary tract cancer prognostic and predictive genomics

Sebastian Mondaca<sup>1,2</sup>, Bruno Nervi<sup>2</sup>, Mauricio Pinto<sup>2</sup>, Ghassan K. Abou-Alfa<sup>1,3</sup>

<sup>1</sup>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>2</sup>Department of Hematology and Oncology, Pontificia Universidad Católica de Chile, Santiago, Chile; <sup>3</sup>Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA

**Contributions:** (I) Conception and design: All authors; (II) Administrative support: S Mondaca, M Pinto; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

**Correspondence to:** Ghassan Abou-Alfa, MD, MBA. Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 E66th Street, New York, NY 10065, USA. Email: abou-alf@MSKCC.ORG.

**Abstract:** Biliary tract cancer (BTC) is comprised of intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (EHC) and gallbladder cancer (GBC). These tumors arise in the biliary epithelium, share histological characteristics and are associated with grim prognosis even when diagnosed at early stages. Moreover, its relatively low incidence in developed countries has precluded the development of clinical trials addressing specific differences among BTC subgroups in terms of their biology, treatment response and clinical outcomes. In this scenario, the development of effective treatment strategies for patients has been rather modest. To date, the combination of cisplatin plus gemcitabine remains as the standard first line therapy in advanced disease and after progression to this regimen there are limited treatment options. Next generation sequencing (NGS) studies have assessed the distribution of driver genes and potentially actionable genomic alterations among ICC, EHC and GBC. Here, we outline genomic differences among these subsets and describe key milestones in order to develop novel targeted drugs against BTCs. Although the early results of several studies are promising, international collaboration is critical to conduct adequately-powered trials, enrolling patients from high-incidence countries.

**Keywords:** Gallbladder cancer (GBC); biliary tract cancer (BTC); genomics; next generation sequencing (NGS)

Submitted Jun 04, 2019. Accepted for publication Jul 11, 2019.

doi: 10.21037/cco.2019.07.06


**View this article at:** <http://dx.doi.org/10.21037/cco.2019.07.06>

## Introduction

Biliary tract cancer (BTC) is the second most common type of hepatobiliary cancer and is comprised of intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (EHC) and gallbladder cancer (GBC). EHC can be further divided into perihilar, proximal or distal cholangiocarcinoma (1). In Western countries, ICC and EHC incidence are modest, ranging from 0.35 to 2 per 100,000/year. However, there are considerable regional differences associated with risk factors such as endemic liver fluke infection (*Opisthorchis viverrini*) in Asia (2). The highest incidence rates of GBC (up to 7.5 per 100,000 for men and 23 per 100,000 for women) are found among populations living in the Andean region (Chile, Bolivia),

North-American Indians, Mexican Americans (3). As such, in Chile GBC is the second leading cause of death for women after breast cancer. Similarly, India accounts for a high burden of GBC worldwide with an age-standardized rate of 2.1 and 1.8 per 100,000 for incidence and mortality in women, respectively (4). GBC is closely associated with cholelithiasis and chronic gallbladder inflammation (cholecystitis). Other risk factors that might explain these regional differences in GBC incidence include chronic *Salmonella* or *Helicobacter bilis* infection, Native American ancestry and aflatoxin exposure (5-7).

All BTCs arise in the biliary epithelium; they are associated with poor outcomes even when diagnosed at early stage (8,9). Although BTCs share some histological characteristics and features, there are important differences



**Figure 1** Frequent genomic alterations in biliary tract cancer subtypes. Actionability of alterations is described according to the OncoKB precision oncology knowledge base.

among them in terms of disease behavior, molecular profiles, and sensitivity to therapy (10). For example, GBC has been associated with worse prognosis compared to cholangiocarcinoma, however it has a greater response rate to chemotherapy (11). Historically, BTCs have been grouped together for the purpose of clinical trial accrual, however, genetic profiling has opened the opportunity to view them as molecularly distinct entities and enabled the targeting of specific genomic alterations. Herein we describe the genomic landscape of BTCs with a special comparative focus on relevant differences across BTC subgroups and biomarkers with potential clinical implications. *Figure 1* summarizes the most prevalent genomic alterations observed across different BTC subtypes and their current actionability according to the OncoKB precision oncology database (12).

## Molecular landscape of BTC

### Prevalent genomic alterations in BTC

Early BTC studies defined relevant oncogenes and tumor suppressor genes using polymerase chain reaction, Sanger sequencing, single-strand confirmation polymorphism and fluorescent *in situ* hybridization among other techniques. However, the actual frequency of these events and their relative distribution in different subgroups was difficult to assess. This can be explained by several reasons including sample heterogeneity, the application of a

variety of different methodologies and a high stromal cell content in samples that may dilute out cancer-cell specific nucleic acids (10). Following the introduction of next generation sequencing (NGS), most of these issues have been surpassed (*Table 1*) (13-20). Indeed, NGS assays are highly sensitive, able to analyze a large panel of genes, and detect novel mutations, small insertions or deletions (indels), copy number alterations, and select gene fusions and rearrangements from small amounts of sample (21). A pioneer study used NGS to characterize 54 ICC *Opisthorchis viverrini*-related cholangiocarcinoma cases and found mutations in *TP53* (44.4%), *KRAS* (16.7%), and *SMAD4* (16.7%) (22). Subsequent studies have applied a variety of NGS platforms allowing a thorough comparison among BTC subgroups. A larger study analyzed 412 ICC, 57 EHC and 85 GBC cases that underwent genomic sequencing with the hybrid capture-based NGS platform FoundationOne (14). Interestingly, this study demonstrated significant differences among these 3 subtypes. Potentially actionable mutations were found in *FGFR2* and *IDH1/2*, however, these were mostly limited to ICC with a prevalence of 11% and 20%, respectively. Also, *ERBB2* amplification was more frequently observed in GBC (16%) and EHC (11%) versus ICC (3%). Similarly, a prospective study analyzed 195 cholangiocarcinomas using the targeted MSK-IMPACT platform (15) and found that *FGFR2* fusions and *IDH1*, *BAP1* and *TP53* mutations occurred with greater frequency among ICCs, whereas *KRAS*, *SMAD4*,

**Table 1** Main studies reporting molecular alterations associated with biliary tract cancers

First author	Platform/genes analyzed	N of patients	Genomic alterations (%)
Nakamura <i>et al.</i> (13)	WES	260	ICC: <i>KRAS</i> 25%, <i>FGFR2</i> 8%, <i>IDH1</i> 6%; EHC: <i>TP53</i> 26%, <i>KRAS</i> 12%, <i>SMAD4</i> 10%; GBC: <i>TP53</i> 43%, <i>ARID2</i> 18%, <i>EGFR</i> 18%
Javle <i>et al.</i> (14)	HC NGS 182	ICC 412; EHC 57; GBC 85	ICC: <i>TP53</i> 27%, <i>KRAS</i> 22%, <i>IDH1</i> 16%; EHC: <i>KRAS</i> 42%, <i>TP53</i> 40%, <i>SMAD4</i> 21%; GBC: <i>TP53</i> 59%, <i>CDKN2A/B</i> 19%, <i>ERBB2</i> 16%
Lowery <i>et al.</i> (15)	HC NGS 341/410	ICC 158; EHC 37	ICC: <i>IDH1</i> 30%, <i>BAP1</i> 20%, <i>FGFR2</i> 14%; EHC: <i>KRAS</i> 38%, <i>TP53</i> 49%, <i>SMAD4</i> 30%
Narayan <i>et al.</i> (16)	HC NGS 341/410	GBC 81	<i>TP53</i> 58%, <i>SMAD4</i> 31%, <i>ARID1A</i> 25%
Churi <i>et al.</i> (17)	AB NGS 46	ICC 55; EHC 20	ICC: <i>TP53</i> 29%, <i>KRAS</i> 24%, <i>IDH</i> 24%; EHC: <i>KRAS</i> 40%, <i>TP53</i> 45%, <i>SMAD4</i> 25%
Li <i>et al.</i> (18)	WES	GBC 57	<i>TP53</i> 47%, <i>ERBB3</i> 12%, <i>KRAS</i> 8%
Ross <i>et al.</i> (19)	HC NGS 182	ICC 28	<i>ARID1A</i> 36%, <i>IDH1/2</i> 36%, <i>TP53</i> 36%
Zou <i>et al.</i> (20)	WES	ICC 102	<i>TP53</i> 38%, <i>KRAS</i> 17%, <i>ARID1A</i> 7%

WES, whole-exome sequencing; HC NGS, hybrid capture next generation sequencing; AB NGS, amplicon-based next generation sequencing; ICC, intrahepatic cholangiocarcinoma; EHC, extrahepatic cholangiocarcinoma; GBC, gallbladder cancer.

and *STK11* alterations were more commonly seen in EHCs.

### Molecular subtypes BTC

Additionally, NGS studies have contributed to refine etiologically distinct BTC subtypes. A study by the International Cancer Genome Consortium included a group of 489 ICC and EHC patients who underwent genomic, epigenomic, and transcriptomic analyses. Integrative clustering was primarily based on 71 patients who were assessed by whole-genome sequencing. This analysis found 4 clusters characterized by different clinical features including proportion of ICC and EHC and genomic alterations (23): Cluster 1 comprised mostly fluke-associated tumors that also displayed hypermethylation of CpG island-promoters, and enrichment of *ARID1A* and *BRCA1/2* mutations. Cluster 2 was characterized by a mix of fluke-positive and fluke-negative tumors, and upregulated *CTNNB1* and *AKT1* expression. Clusters 1 and 2 were significantly enriched in *TP53* mutations and *ERBB2* amplifications. Clusters 3 and 4 comprised almost exclusively fluke-negative tumors. Cluster 3 displayed the highest level of copy number alterations, including enrichment of amplifications at 2p and 2q; these tumors also exhibited upregulation of immune checkpoint genes such as PD-1 and PD-L2. Cluster 4 was characterized by

upregulation of *FGFR* family and PI3K pathways signatures along with frequent *BAP1* and *IDH1/2* mutations. Clusters 1 and 2 were enriched in EHC, whereas Clusters 3 and 4 were mostly ICC cases. Similarly, a Chinese study used a whole-exome sequencing approach and included 102 ICC patients. This study found that *TP53*-defective patients were more likely to be HBsAg-seropositive (P=0.021), also *KRAS* mutations were very infrequent in this group (20).

### Germline alterations in BTC

Studies have determined that 10–20% of BTC patients display germline mutations on cancer-prone genes. Indeed, a recent study analyzed germline variants of selected genes in a cohort of 146 Japanese BTC patients. Germline variants were confirmed by the Sanger method and found a 11% of deleterious mutations in several genes including *BRCA1*, *BRCA2*, *RAD51D*, *MLH1*, or *MSH2* (24). A similar study found a higher prevalence (20%) of germline pathogenic or likely pathogenic genomic alterations (25). In this study, a total of 78 patients (ICC =52, EHC =13 and GBC =13) were analyzed using the NGS MSK-IMPACT platform. This platform includes 76 genes associated with hereditary cancer predisposition. The most frequent germline mutations were found in *BRCA2* (5.1%), *APC* (3.8%) and *MUTYH* (3.8%) genes. These findings support

germline analysis in BTC patients in view of screening and therapeutic implications. Series of BTC patients with germline mutations in mismatch repair (MMR) genes such as *MLH1* or *MSH2* suggest that this phenomenon is infrequent and represent a small minority of patients with MMR-deficient tumors (26).

### Potential prognostic and predictive genomic markers in BTC

#### *FGFR*

The *FGFR* family comprises four transmembrane tyrosine kinase receptors (namely *FGFR1*, -2, -3, and -4). Downstream signaling of activated *FGFRs* involves activation of the mitogen-activated protein kinase (MAPK) and/or phosphoinositide-3 kinase—Akt pathways. *FGFR* gene-fusions (particularly *FGFR2*) are considered a promising target for therapeutic inhibition. In contrast, the predictive role of *FGFR1/2/3* mutations is more uncertain. As mentioned, *FGFR2* fusions that involve its kinase domain are commonly seen in ICCs ranging from 8% to 14%. The most frequent fusion partners for *FGFR2* is *BICC1*. However, a number of partners have been described in the literature, including *KIAA1217*, *AHCYL1*, *TACC1*, *MGEA5*, and *PPHLN* (15,27).

In a recent phase II study, infiratinib, a selective *FGFR1-3* kinase inhibitor, was studied in cholangiocarcinoma patients who harbored *FGFR2* fusions or other *FGFR* alterations (28). The response rate among patients with *FGFR2* fusions was 19%, however no responses were seen in patients with other genetic *FGFR* alterations. *FGFR* plays an important role in phosphate homeostasis. Consequently, hyperphosphatemia has been a relevant on target toxicity of this class of drugs. Indeed, this trial found a 16% of patients were affected by grade 3–4 hyperphosphatemia. A phase III trial evaluating first-line infiratinib versus chemotherapy in ICC patients with *FGFR2* fusions has started accrual (NCT03773302). Erdafitinib is another oral pan-*FGFR* inhibitor that has also been evaluated in ICCs. The LUC2001 phase II trial (NCT02699606) evaluated 11 ICC patients with different genetic alterations in *FGFR2* or *FGFR3* (29). Given the abovementioned risk of hyperphosphatemia, investigators applied a dosing schedule based on serum phosphate levels. Within this group, 5 out of 11 patients showed partial responses. Interestingly, all responders had *FGFR2* alterations. Even though investigators used an up-titration protocol, hyperphosphatemia was frequent (10/11 patients). Despite

this, all patients continued their treatments. Interestingly, this drug has been recently approved by American Food and Drug Administration (FDA) for metastatic urothelial carcinoma, with susceptible *FGFR3* or *FGFR2* genetic alterations based on the results of the BLC2001 trial (30). A recent phase I trial evaluated the *FGFR* inhibitor DEBIO 1347 in biliary tract malignancies (31). Eight BTC patients were treated in the dose escalation cohort of this study and they reported a 12.5% response rate. Grade 3–4 hyperphosphatemia was seen in 21% of patients. The maximum tolerated dose was not reached; however, dermatologic toxicity became sometimes dose-limiting beyond the dose-limiting toxicity period. TAS-120 is highly selective, irreversible *FGFR1-4* inhibitor that was also studied in a phase I trial including BTC patients harboring *FGFR* alterations. The outcomes of the subgroup of patients with *FGFR2* gene fusions (n=28) were reported showing an objective response rate of 25% (32). This drug has also demonstrated preclinical activity against multiple *FGFR2* mutations shown to confer resistance to other *FGFR* inhibitors such as *FGFR2* V565F gatekeeper mutation. A recent study showed that TAS-120 was active in four patients with *FGFR2*-fusion-positive ICC who developed resistance to infiratinib or Debio 1347; two of these patients achieved a partial response and two achieved stable disease by RECIST v1.1 criteria (33). In 3 of these patients *FGFR2* mutations associated with resistance to *FGFR* inhibitors were detected in tissue or circulating tumor DNA before starting TAS-120. Currently, the FOENIX-101 phase II trial is evaluating the efficacy of TAS-120 in patients with ICC harboring *FGFR2* gene rearrangements (NCT02052778). The *FGFR* inhibitor pemigatinib has also shown promising results in a phase II trial that included a cohort with tumors with *FGFR2* translocations (mostly ICC) (34). These results have provided foundation for a phase III trial assessing the efficacy of this drug versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with *FGFR2* rearrangement (NCT03656536). Likewise, the *FGFR* inhibitor derazantinib had an encouraging 21% response rate in patients with advanced ICC with *FGFR2* fusion in a phase I/II trial (35). A phase II trial assessing the efficacy of this drug in this population is ongoing (NCT03230318).

#### *IDH1/2*

Somatic mutations in *IDH* enzymes are observed in 5–36% of ICCs (27). These enzymes are part of the tricarboxylic

acid cycle and catalyze the interconversion of isocitrate to alpha-ketoglutarate (36). Cancer-associated mutations in *IDH1/2* result in high levels of (R)-2-hydroxyglutarate, an onco-metabolite that seems to be associated with alterations in several cell processes including redox state and DNA repair mechanisms, also modulating the activity of epigenetic tumor suppressor enzymes (37-39). In addition to its functional impact on cancer progression *IDH1/2* mutations have been implicated in ICC prognosis. Some studies have found an association between *IDH1/2* mutations and improved clinical outcomes (40,41). However, this is a controversial issue since other studies have not found significant differences (42). Both *IDH1* and *IDH2* inhibitors have shown robust activity in preclinical models for solid tumors and leukemia (43,44). Ivosidenib is a first-in-class mutant *IDH1* inhibitor that has been evaluated in a phase I study in *IDH1*-mutant advanced cholangiocarcinoma (45). This trial included 73 BTC patients (dose escalation n=24 and expansion n=49) and reported an objective response rate of 5% and a 12-month progression-free survival of 22%. Also, 3% of patients displayed grade 3-4 toxicity. A randomized phase III trial (ClarIDHy) of ivosidenib in this population is currently ongoing (NCT02989857) and recently it has been reported in a press release that it has achieved its primary endpoint (46). ClarIDHy did not include GBC patients since *IDH-1* mutations are very infrequent in this group. BAY 1436032 is another oral inhibitor against mutant *IDH1*, whose safety, tolerability and preliminary anti-tumor activity are under evaluation in a phase I basket trial (NCT02746081) including mutant *IDH1* BTC patients (47). *IDH2* mutations are found less frequently in ICC (3% to 5%) and they also have been described as an acquired resistance mutation to *IDH1* inhibition in this disease (48). Enasidenib is a mutant *IDH2* inhibitor that has been approved for *IDH2*-mutant acute myeloid leukaemia, however, there is not data supporting activity of this drug in *IDH2*-mutant BTC.

## HER2

Amplification of *ERBB2* (also known as *HER2*) occurs in 3% to 19% of BTCs and is more frequent in GBC and EHC versus ICC (14,49). The study of *HER2* as an actionable target in BTC has been challenging. A phase II trial led by the American National Cancer Institute (NCT00478140) tried to assess the efficacy of trastuzumab in *HER2*-overexpressed BTC, however, this study was closed due to slow accrual. Subsequently, two phase II studies evaluating

the activity lapatinib in BTC did not show any responses, however these studies included an unselected population (50,51). Currently, a multi-cohort phase II trial in China is set to evaluate the combination of gemcitabine and oxaliplatin with trastuzumab in *ERBB2*-amplified BTC (NCT02836847). A limited number of BTC patients with *ERBB2* amplification have been recruited in basket trials demonstrating the efficacy of anti-*HER2* therapies. For example, the MyPathway trial included seven *HER2* overexpressed/amplified BTC patients treated with the combination of the anti-*HER2* antibodies trastuzumab and pertuzumab. In these patients the objective response was 29% (52). A similar response rate (17%) was recently shown for trastuzumab emtansine in this population (1 in 6 patients) (53). The antibody drug conjugate trastuzumab deruxtecan and the bispecific *HER2*-targeted antibody ZW25 have shown interesting activity in non-breast non-gastric *HER2*-amplified tumors in phase I trials (54,55). *HER2*-amplified BTCs have not been adequately represented in these studies, however, it is an interesting population to be included in future trials.

*HER2* activating mutations have been described in between 1-8% of BTC and the potential therapeutic significance of these mutations is controversial. Interestingly, in a recent basket trial evaluating the efficacy of the pan-*HER* tyrosine kinase inhibitor neratinib in *HER2*-mutant tumors, nine BTC patients were enrolled. The reported response rate in this subgroup was 22% providing preliminary evidence of actionability (56).

## BRAF

*BRAF* encodes a serine/threonine protein directly downstream from *RAS* in the *MAPK* cascade. The most frequent *BRAF* mutation is located in the V600 codon. In BTC patients *BRAF* mutations occur in 1% to 4% of ICC patients, while they are extremely infrequent in EHC or GBC (13,57). The phase II VE-BASKET trial included 8 *BRAF*-mutant BTC patients and reported 1 partial response (12%) (58). Subsequently, results of the ROAR Basket Trial demonstrated a 42% of response rate to the *RAF* inhibitor dabrafenib and *MEK* inhibitor trametinib in V600E *BRAF*-mutant BTC (59).

## DDR

Alterations in DNA repair genes are relatively frequent in BTC including *MSH6*, *BAP1*, *ATM*, *MLH1*, *MSH2*, *BRCA1*

**Table 2** Clinical trial efficacy data for targetable genomic alterations in biliary tract cancers

Alteration	Therapy	N, patients	ORR (%)	Median PFS (months)	Reference
<i>FGFR2</i>	Infigratinib	61	15	5.8	(28)
	Erdafitinib	11	46	5.6	(29)
	Debio 1347	8	12.5	NR	(31)
	TAS-120	28	25	NR	(32)
	Derazantinib	29	21	5.7	(35)
<i>IDH1/2</i>	Ivosidenib	73	5	3.8	(45)
<i>HER2</i>	Trast + P	7 (amp)	29	NR	(52)
	T-DM1	6 (amp)	17	NR	(53)
	Neratinib	9 (mut)	22	NR	(56)
<i>BRAF</i>	Vemurafenib	8	12	NR	(58)
	D + T	33	42	7.2	(59)
<i>EGFR</i>	Erl + Bev	49	12	4.4	(71)
	GEMOX + Erl	135 vs. 133	30 vs. 16 <sup>‡</sup>	5.8 vs. 4.2 <sup>†</sup>	(72)
	Gem + C	44	20	5.8	(73)
	GEMOX + C	76 vs. 74	24 vs. 23 <sup>†</sup>	6.1 vs. 5.5 <sup>†</sup>	(74)
	GEMOX + P	46	33	8.3	(75)

<sup>†</sup>, not significant; <sup>‡</sup>, statistically significant difference. Trast, trastuzumab; P, pertuzumab; T-DM1, trastuzumab emtansine; D, dabrafenib; T, trametinib; Erl, erlotinib; GEMOX, gemcitabine and oxaliplatin; C, cetuximab; P, panitumumab; NR, not reported; amp, amplified; mut, mutant.

and *BRCA2*. Indeed, studies demonstrate that up to 16% of ICC and 45% of EHC patients display mutations in these genes (17). DNA-repair deficient cells (particularly *BRCA1* or 2 mutants) can accumulate double-strand DNA breaks that result in genomic instability, leading to an increased sensitivity to DNA damaging therapies such as platinum compounds or poly ADP-ribose polymerase (PARP) inhibitors (60,61). Several studies have demonstrated the efficacy of PARP inhibitors in *BRCA1/2* mutant breast and ovarian cancer (62-66). A recent series showed that 4 *BRCA1/2*-mutant cholangiocarcinoma patients who received PARP inhibitors had a favorable response. In fact, one of these patients had a progression free survival of 42 months (67). This specific patient had a known pathogenic germline *BRCA2* mutation, however, the predictive features of germline versus somatic mutations remains to be elucidated. Anecdotal responses to PARP inhibitors have also been reported in metastatic *BRCA1* mutant GBC (68). Interestingly, a recent study demonstrated that the accumulation of 2-Hydroxyglutarate associated with IDH mutations can suppress homologous recombination and

thereby induces sensitivity to PARP inhibitors (69). These findings provide the foundations for a trial exploring the anti-tumoral activity of olaparib in solid tumors that harbor *IDH1/2* mutations (NCT03212274).

### *EGFR*

Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor that plays a key role in the cancer cell proliferation and is overexpressed in several solid tumors. Receptor-specific EGF ligands can bind onto EGFR (Erb1), Erb3, or Erb4 (70). Preclinical studies support the relevance of EGFR in the carcinogenesis of BTC, however results from early trials using anti-EGFR therapies have been disappointing (*Table 2*) (71-75), and to date no benefit has been demonstrated even in trials that have excluded *RAS*-mutant tumors.

### *Microsatellite instability (MSI)*

MSI results from defects in the MMR system including

*MLH1*, *PMS2*, *MSH2*, and *MSH6* genes. The dysfunction of this repair system affects DNA proofreading after replication, leading to variable lengths of short tandem repeats, called microsatellites, within noncoding and coding regions (76). This phenomenon is known as MSI and can be attributed to germline mutations in one or several MMR genes that render a nonfunctional protein or to somatic hypermethylation of the *MLH1* promoter that leads to epigenetic silencing. Studies show that 1–10% of BTCs can be categorized as MSI-high. These are more frequent in ICC compared to EHC or GBC (77,78). In localized disease, MSI-H GBC might be associated with better outcomes as it has been demonstrated in localized colorectal and gastric cancer, however, this needs further confirmation (79–81). MMR-deficiency has been shown to predict response of solid tumors to immunotherapy with PD-1 checkpoint inhibitors (82). Consequently, the FDA has provided a tissue/site-agnostic approval for pembrolizumab for this indication. Interestingly, in the pivotal KEYNOTE16 phase II study, a total of 4 MSI-high cholangiocarcinoma patients received pembrolizumab: 1 had a partial response and 3 had stable disease (83).

### ***CDKN2A***

Cyclin-dependent kinase inhibitor 2A (*CDKN2A*, also known as P16INK4A) is a tumor suppressor gene that encodes two proteins via an alternative splicing: p16INK4A and p14ARF. These proteins can act as inhibitors of cyclin-dependent kinase 4 (CDK4) and/or 6 (CDK6) thereby regulating the cell cycle. Altered *CDKN2A* is observed in many malignancies, however, its prognostic relevance varies by tumor type (84). In BTCs, *CDKN2A* is frequently silenced by hypermethylation, by homozygous deletion, or by inactivating mutations (10). Studies demonstrate that *CDKN2A* alterations are more frequently seen in GBC versus ICC or EHC (14) and have been associated with decreased survival (85). Although *CDKN2A* alterations are not considered actionable *per se*, homozygous *CDKN2A* loss is usually concomitant with methylthioadenosine phosphorylase (*MTAP*) gene deletions, which might be targetable. *MTAP* encodes a key enzyme in the methionine salvage pathway (86) and *MTAP*-deficient cells rely on protein arginine methyl-transferase 5 (PRMT5) for purine biosynthesis. Preclinical studies demonstrate that *MTAP*-deficient cancers depend on methionine adenosyltransferase II alpha (*MAT2A*) to produce S-adenosylmethionine, an essential PRMT5-substrate for survival of these cells (87).

Currently, a phase I trial is set to evaluate the maximum tolerated dose, safety and efficacy of AG-270, a *MAT2A* inhibitor in solid tumors or lymphoma with homozygous loss of *CDKN2A* or *MTAP* (NCT03435250).

### ***NTRK***

The *NTRK* family includes three genes, *NTRK1*, *NTRK2*, and *NTRK3*, which encode three tropomyosin receptor kinase (TRK) proteins—TRKA, TRKB, and TRKC, respectively. Studies have identified *NTRK* fusions at low frequencies across various tumor types, including BTCs (88). Larotrectinib is now a FDA-approved selective small-molecule inhibitor of all three TRK proteins. Its use is approved for adult and pediatric patients with solid tumors that harbor *NTRK* gene fusions. Approval was based on the results of three studies: a phase I study in adults, a phase I/II study in children, and a phase II basket study in adolescents and adults. Altogether these studies included 55 *NTRK* fusion cases and reported a response rate of 80% (89). Two cholangiocarcinoma patients were included in these studies; one had a partial response and the other had progression of disease.

### **Conclusions**

A deeper understanding of the molecular landscape and activated pathways involved in the carcinogenesis of BTCs has enabled to recognize BTCs subtypes as different entities. Furthermore, it has also guided the development of several novel drugs, which has derived into multiple ongoing phase II and III trials. Some of these trials have already shown preliminary efficacy on clinical outcomes and represent one step further towards becoming a standard treatment. Interestingly, some of the abovementioned targetable genomic alterations such as *FGFR2* fusions, *IDH1* and *BRAF* mutations, and *ERBB2* amplifications have already been identified in circulating-tumor DNA (ctDNA) from ~20% of BTC patients (90). As has been discussed, BTCs are more prevalent in developing countries. One significant barrier to conduct adequately-powered trials to demonstrate definitive efficacy of these targeted therapies in BTC, is that the access to tissue and ctDNA NGS is limited in these countries. Consequently, international collaboration in coming years will play a key role in order to provide the expertise and resources to develop such studies. Hopefully, these initiatives, along with lowering costs of sequencing technologies, will increase the enrollment of BTC cases

into molecularly-designed trials eventually leading to more treatment options for these patients in need.

## Acknowledgments

None.

## Footnote

*Conflicts of Interest:* The authors have no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

## References

- Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). *Nat Rev Gastroenterol Hepatol* 2016;13:261-80.
- Bridgewater JA, Goodman KA, Kalyan A, et al. Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling. *Am Soc Clin Oncol Educ Book* 2016;35:e194-203.
- Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. *Nat Rev Cancer* 2004;4:695-706.
- Are C, Ahmad H, Ravipati A, et al. Global epidemiological trends and variations in the burden of gallbladder cancer. *J Surg Oncol* 2017;115:580-90.
- Koshiol J, Wozniak A, Cook P, et al. Salmonella enterica serovar Typhi and gallbladder cancer: a case-control study and meta-analysis. *Cancer Med* 2016;5:3310-235.
- Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. *Int J Cancer* 2006;118:1591-602.
- Nogueira L, Foerster C, Groopman J, et al. Association of aflatoxin with gallbladder cancer in Chile. *JAMA* 2015;313:2075-7.
- Roa I, Ibacache G, Muñoz S, et al. Gallbladder cancer in Chile: Pathologic characteristics of survival and prognostic factors: analysis of 1,366 cases. *Am J Clin Pathol* 2014;141:675-82.
- Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. *Ann Surg* 2001;234:507-17; discussion 17-9.
- Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. *J Clin Oncol* 2010;28:3531-40.
- Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. *Br J Cancer* 2007;96:896-902.
- Chakravarty D, Gao J, Phillips SM, et al. OncoKB: A Precision Oncology Knowledge Base. *JCO Precis Oncol* 2017;2017. doi: 10.1200/PO.17.00011.
- Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. *Nat Genet* 2015;47:1003-10.
- Javle M, Bekaii-Saab T, Jain A, et al. Biliary cancer: Utility of next-generation sequencing for clinical management. *Cancer* 2016;122:3838-47.
- Lowery MA, Ptashkin R, Jordan E, et al. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. *Clin Cancer Res* 2018;24:4154-61.
- Narayan RR, Creasy JM, Goldman DA, et al. Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations. *Cancer* 2019;125:575-85.
- Churi CR, Shroff R, Wang Y, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. *PLoS One* 2014;9:e115383.
- Li M, Zhang Z, Li X, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. *Nat Genet* 2014;46:872-6.
- Ross JS, Wang K, Gay L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. *Oncologist* 2014;19:235-42.
- Zou S, Li J, Zhou H, et al. Mutational landscape of intrahepatic cholangiocarcinoma. *Nat Commun* 2014;5:5696.
- Atreya CE, Yaeger R, Chu E. Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches. *Am Soc Clin Oncol Educ Book* 2017;37:246-56.
- Ong CK, Subimerb C, Pairojkul C, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. *Nat Genet* 2012;44:690-3.
- Jusakul A, Cutcutache I, Yong CH, et al. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. *Cancer Discov*

- 2017;7:1116-35.
24. Wardell CP, Fujita M, Yamada T, et al. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. *J Hepatol* 2018;68:959-69.
  25. Lowery MA, Jordan E, Kemel Y, et al. A prospective analysis of germline alterations (GA) in biliary tract cancer (BTC). *J Clin Oncol* 2017;35:4085.
  26. Cloyd JM, Chun YS, Ikoma N, et al. Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Biliary Tract Cancers Associated with Lynch Syndrome. *J Gastrointest Cancer* 2018;49:93-6.
  27. Valle JW, Lamarca A, Goyal L, et al. New Horizons for Precision Medicine in Biliary Tract Cancers. *Cancer Discov* 2017;7:943-62.
  28. Javle M, Lowery M, Shroff RT, et al. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. *J Clin Oncol* 2018;36:276-82.
  29. Chen Y, Park JO, Su W, et al. Preliminary results of a ph2a study to evaluate the clinical efficacy and safety of erdafitinib in Asian patients with biomarker-selected advanced cholangiocarcinoma (CCA). *Ann Oncol* 2018;29:viii205-70.
  30. Loriot Y, Necchi A, Park SH, et al. Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing. *J Clin Oncol* 2018;36:411.
  31. Voss MH, Hierro C, Heist RS, et al. A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. *Clin Cancer Res* 2019;25:2699-707.
  32. Meric-Bernstam F, Arkenau H, Tran B, et al. O-001 Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. *Ann Oncol* 2018;29. doi: 10.1093/annonc/mdy149.
  33. Goyal L, Shi L, Liu LY, et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. *Cancer Discov* 2019. doi: 10.1158/2159-8290.CD-19-0182.
  34. Hollebecque A, Borad M, Sahai V, et al. 756P Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations. *Ann Oncol* 2018;29. doi: 10.1093/annonc/mdy282.139.
  35. Mazzaferro V, El-Rayes BF, Droz Dit Busset M, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. *Br J Cancer* 2019;120:165-71.
  36. Losman JA, Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. *Genes Dev* 2013;27:836-52.
  37. Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. *J Natl Cancer Inst* 2010;102:932-41.
  38. Yen KE, Bittinger MA, Su SM, et al. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. *Oncogene* 2010;29:6409-17.
  39. Molenaar RJ, Maciejewski JP, Wilmink JW, et al. Wild-type and mutated IDH1/2 enzymes and therapy responses. *Oncogene* 2018;37:1949-60.
  40. Wang P, Dong Q, Zhang C, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. *Oncogene* 2013;32:3091-100.
  41. Cercek A, Kemeny NE, Boerner T, et al. A bi-institutional phase II study of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (Dex) combined with systemic gemcitabine and oxaliplatin (GemOx) for unresectable intrahepatic cholangiocarcinoma (ICC). *J Clin Oncol* 2018;36:4092.
  42. Goyal L, Govindan A, Sheth RA, et al. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. *Oncologist* 2015;20:1019-27.
  43. Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. *Science* 2013;340:626-30.
  44. Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. *Science* 2013;340:622-6.
  45. Lowery MA, Abou-Alfa GK, Burris HA, et al. Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts. *J Clin Oncol* 2017;35:4015.
  46. Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant

- Cholangiocarcinoma Patients. Available online: <https://agiospharmaceuticalsinc.gcs-web.com/news-releases/news-release-details/agios-announces-randomized-phase-3-claridhy-trial-tibsovor>. Accessed May 25, 2019.
47. Pellino A, Loupakis F, Cadamuro M, et al. Precision medicine in cholangiocarcinoma. *Transl Gastroenterol Hepatol* 2018;3:40.
  48. Harding JJ, Lowery MA, Shih AH, et al. Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. *Cancer Discov* 2018;8:1540-7.
  49. Galdy S, Lamarca A, McNamara MG, et al. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? *Cancer Metastasis Rev* 2017;36:141-57.
  50. Peck J, Wei L, Zalupski M, et al. HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib. *Oncology* 2012;82:175-9.
  51. Ramanathan RK, Belani CP, Singh DA, et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. *Cancer Chemother Pharmacol* 2009;64:777-83.
  52. Hainsworth JD, Meric-Bernstam F, Swanton C, et al. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. *J Clin Oncol* 2018;36:536-42.
  53. Li BT, Makker V, Buonocore DJ, et al. A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers. *J Clin Oncol* 2018;36:2502.
  54. Iwata H, Tamura K, Doi T, et al. Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts. *J Clin Oncol* 2018;36:2501.
  55. Meric-Bernstam F, Beeram M, Mayordomo JI, et al. Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers. *J Clin Oncol* 2018;36:2500.
  56. Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. *Nature* 2018;554:189-94.
  57. Goepfert B, Frauenschuh L, Renner M, et al. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. *Mod Pathol* 2014;27:1028-34.
  58. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. *N Engl J Med* 2015;373:726-36.
  59. Wainberg ZA, Lassen UN, Elez E, et al. Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E-mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial. *J Clin Oncol* 2019;37:187.
  60. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* 2005;434:917-21.
  61. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* 2005;434:913-7.
  62. Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. *N Engl J Med* 2017;377:523-33.
  63. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. *N Engl J Med* 2018;379:753-63.
  64. Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. *N Engl J Med* 2018;379:2495-505.
  65. Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2017;390:1949-61.
  66. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. *N Engl J Med* 2016;375:2154-64.
  67. Golan T, Raitses-Gurevich M, Kelley RK, et al. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. *Oncologist* 2017;22:804-10.
  68. Xie Y, Jiang Y, Yang XB, et al. Response of BRCA1-mutated gallbladder cancer to olaparib: A case report. *World J Gastroenterol* 2016;22:10254-9.
  69. Sulkowski PL, Corso CD, Robinson ND, et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. *Sci Transl Med* 2017;9. doi: 10.1126/scitranslmed.aal2463.
  70. Oyasiji T, Zhang J, Kuvshinoff B, et al. Molecular Targets in Biliary Carcinogenesis and Implications for Therapy. *Oncologist* 2015;20:742-51.
  71. Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. *J*

- Clin Oncol 2010;28:3491-7.
72. Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol* 2012;13:181-8.
  73. Borbath I, Ceratti A, Verslype C, et al. Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology. *Ann Oncol* 2013;24:2824-9.
  74. Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. *Lancet Oncol* 2014;15:819-28.
  75. Jensen LH, Lindebjerg J, Ploen J, et al. Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer. *Ann Oncol* 2012;23:2341-6.
  76. Vilar E, Taberero J. Molecular dissection of microsatellite instable colorectal cancer. *Cancer Discov* 2013;3:502-11.
  77. Winkelmann R, Schneider M, Hartmann S, et al. Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital. *Int J Mol Sci* 2018;19. doi: 10.3390/ijms19051421.
  78. Silva VW, Askan G, Daniel TD, et al. Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. *Chin Clin Oncol* 2016;5:62.
  79. Roa JC, Roa I, Correa P, et al. Microsatellite instability in preneoplastic and neoplastic lesions of the gallbladder. *J Gastroenterol* 2005;40:79-86.
  80. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. *J Clin Oncol* 2010;28:3219-26.
  81. Choi YY, Kim H, Shin SJ, et al. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study. *Ann Surg* 2019;270:309-16.
  82. Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *N Engl J Med* 2015;372:2509-20.
  83. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science* 2017;357:409-13.
  84. Zhao R, Choi BY, Lee MH, et al. Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer. *EBioMedicine* 2016;8:30-9.
  85. Ueki T, Hsing AW, Gao YT, et al. Alterations of p16 and prognosis in biliary tract cancers from a population-based study in China. *Clin Cancer Res* 2004;10:1717-25.
  86. Zhang H, Chen ZH, Savarese TM. Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines. *Cancer Genet Cytogenet* 1996;86:22-8.
  87. Marjon K, Cameron MJ, Quang P, et al. MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis. *Cell Rep* 2016;15:574-87.
  88. Stransky N, Cerami E, Schalm S, et al. The landscape of kinase fusions in cancer. *Nat Commun* 2014;5:4846.
  89. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. *N Engl J Med* 2018;378:731-9.
  90. Mody K, Kasi PM, Yang J, et al. Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers. *JCO Precis Oncol* 2019. doi: 10.1200/PO.18.00324.

**Cite this article as:** Mondaca S, Nervi B, Pinto M, Abou-Alfa GK. Biliary tract cancer prognostic and predictive genomics. *Chin Clin Oncol* 2019;8(4):42. doi: 10.21037/cco.2019.07.06